id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-339669-p61j2caf	Monzani, Alice	QTc evaluation in COVID‐19 patients treated with chloroquine/hydroxychloroquine	2020-05-18		.txt	text/plain	1244	63	44	In late December 2019, a cluster of pneumonia cases caused by a novel coronavirus occurred in Wuhan, China and has spread rapidly initially throughout Europe and later USA (1). In late December 2019, a cluster of pneumonia cases caused by a novel coronavirus occurred in Wuhan, China, and has spread rapidly initially throughout Europe and later in the United States. Despite poor real clinical evidence of unequivocal beneficial effect of chloroquine/hydroxychloroquine (CQ/HCQ), the absence of an effective COVID-19 treatment and the social pressure raised the demand of these drugs for its compassionate use, both in hospital and outpatient settings. 10 High-dosed HCQ showed promising potential effect in reducing SARS-CoV-2 viral load in COVID-19 patients with enhanced effects in combination with azithromycin or several antiviral drugs. In so forth, we believe that is probably time to have prospective clinical trials that will evaluate the safety and efficacy of HCQ during treatment of COVID-infected patients.	./cache/cord-339669-p61j2caf.txt	./txt/cord-339669-p61j2caf.txt